NASDAQ · LEGN
Legend Biotech Corporation
$22.30-$0.23 (-1.02%)
Legend Biotech Corporation’s quoted price sits in the lower half of its reported 52-week range, 40.53% below the high.
Loading market information…
NASDAQ · JANX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Janux Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.55% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Janux Therapeutics, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$0.47. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Janux Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:10 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 8, 2025 |
| -$0.38+11.63% vs estimate |
| $0.00-100.0% vs estimate |
| Q4 2024 | Feb 27, 2025 | -$0.36+26.53% vs estimate | $0.00-100.0% vs estimate |
|---|
| Q3 2024 | Nov 6, 2024 | -$0.51-37.84% vs estimate | $439.00K-70.64% vs estimate |
|---|
THE ANALYST VIEW
16 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 6 contributors · Median target $30.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$22.30-$0.23 (-1.02%)
Legend Biotech Corporation’s quoted price sits in the lower half of its reported 52-week range, 40.53% below the high.
$29.89+$0.23 (+0.78%)
Celldex Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.78% below the high.
$18.29-$0.47 (-2.51%)
Immunome, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.16% below the high.
$7.31-$0.04 (-0.54%)
Immatics N.V.’s quoted price sits in the lower half of its reported 52-week range, 41.1% below the high.
$15.45-$0.11 (-0.71%)
Cullinan Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 33.38% below the high.
$2.29-$0.07 (-2.97%)
CytomX Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.11% below the high.
$1.13+$0.15 (+15.31%)
Veraxa Biotech Holding AG’s quoted price sits in the lower half of its reported 52-week range, 95.87% below the high.
$2.38-$0.09 (-3.64%)
MacroGenics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.15% below the high.
